Vertebral fracture is associated with myocardial infarction in incident hemodialysis patients: a Korean nationwide population-based study.

Publisher: Springer International Country of Publication: England NLM ID: 9100105 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-2965 (Electronic) Linking ISSN: 0937941X NLM ISO Abbreviation: Osteoporos Int Subsets: MEDLINE

Original Publication: London, UK : Springer International, c1990-

Kidney Failure, Chronic*/complications ; Kidney Failure, Chronic*/epidemiology ; Kidney Failure, Chronic*/therapy ; Myocardial Infarction*/complications ; Myocardial Infarction*/epidemiology ; Spinal Fractures*/epidemiology ; Spinal Fractures*/etiology; Humans ; Renal Dialysis ; Republic of Korea/epidemiology ; Risk Factors

Chronic kidney disease (CKD)-mineral and bone disorder suggests that fragile bone and vascular disorder might be connected closely in CKD patients. In this study, fracture event was significantly associated with myocardial infarction (MI) in end-stage renal disease patients on hemodialysis (HD), especially for vertebral fractures.
Introduction: CKD-mineral and bone disorder is characterized by biochemical abnormalities, bone disorders, and vascular calcification. We aimed to verify the association between fracture and MI in CKD patients.
Methods: Records for incident CKD stage 3 to 5 patients and patients who initiated HD between July 2014 and June 2018 were retrieved from the Korean Health Insurance Review & Assessment Service Database. Fractures were defined using diagnostic codes and were classified into vertebral, femoral, and other site fractures. MI was defined using a combination of MI diagnostic codes and related procedure codes. Multiple logistic regressions and 1:1 propensity score matching analysis were conducted.
Results: A total of 38,935 patients (HD, 11,379; pre-dialysis CKD, 27,556) were included in this study. A total of 5,057 (13.0%) patients experienced fracture, and 1,431 (3.7%) patients had MI. Multiple logistic regression analysis showed that fracture was significantly associated with MI in the HD group (odds ratio (OR) 1.34, P = 0.024), but not in the pre-dialysis CKD group (OR 1.04, P = 0.701). After propensity score matching for age, gender, and diabetes mellitus between patients with and without fracture, fracture still significantly correlated with MI in HD patients (OR 1.47, P = 0.034) but not in patients with pre-dialysis CKD (OR 1.04, P = 0.751). Subgroup analysis by fracture site found that vertebral fracture was associated with MI in HD patients (OR 2.11, P = 0.024), but femoral or other site fractures were not.
Conclusion: In HD patients, fracture was significantly associated with MI, especially for vertebral fractures patients.

United States Renal Data System (2018) 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD.
ESRD Registry Committee, Korean Society of Nephrology (2019) Current Renal Replacement therapy in Korea - Insan Memorial Dialysis Registry, 2018.
Kidney Disease: Improving Global Outcomes CKDMBDWG (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl S1–130.
Kidney Disease: Improving global outcomes CKDMBDUWG (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011) 7:1–59.
Desbiens LC, Sidibe A, Ung RV, Fortier C, Munger M, Wang YP, Bisson SK, Marquis K, Agharazii M, Mac-Way F (2018) FGF23-klotho axis, bone fractures, and arterial stiffness in dialysis: a case-control study. Osteoporos Int 29:2345–2353. (PMID: 10.1007/s00198-018-4598-2)
Mirza MA, Karlsson MK, Mellstrom D, Orwoll E, Ohlsson C, Ljunggren O, Larsson TE (2011) Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men. J Bone Miner Res 26:857–864. (PMID: 10.1002/jbmr.263)
Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St. John Sutton M, Ojo A, Gadegbeku C, di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-o M, Kusek JW, Keane MG, Wolf M (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393–4408. (PMID: 10.1172/JCI46122)
Mitsnefes MM, Betoko A, Schneider MF, Salusky IB, Wolf MS, Juppner H, Warady BA, Furth SL, Portale AA (2018) FGF23 and left ventricular hypertrophy in children with CKD. Clin J Am Soc Nephrol 13:45–52. (PMID: 10.2215/CJN.02110217)
Leifheit-Nestler M, Grosse Siemer R, Flasbart K et al (2016) Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant 31:1088–1099. (PMID: 10.1093/ndt/gfv421)
Souma N, Isakova T, Lipiszko D, Sacco RL, Elkind MSV, DeRosa JT, Silverberg SJ, Mendez AJ, Dong C, Wright CB, Wolf M (2016) Fibroblast growth factor 23 and cause-specific mortality in the general population: the northern Manhattan study. J Clin Endocrinol Metab 101:3779–3786. (PMID: 10.1210/jc.2016-2215)
Isakova T, Cai X, Lee J, Xie D, Wang X, Mehta R, Allen NB, Scialla JJ, Pencina MJ, Anderson AH, Talierco J, Chen J, Fischer MJ, Steigerwalt SP, Leonard MB, Hsu CY, de Boer IH, Kusek JW, Feldman HI, Wolf M, Chronic Renal Insufficiency Cohort (CRIC) Study Investigators (2018) Longitudinal FGF23 trajectories and mortality in patients with CKD. J Am Soc Nephrol 29:579–590. (PMID: 10.1681/ASN.2017070772)
Qin Z, Liu X, Song M, Zhou Q, Yu J, Zhou B, Wu Y, He Y, Huang L (2017) Fibroblast growth factor 23 as a predictor of cardiovascular and all-cause mortality in prospective studies. Atherosclerosis 261:1–11. (PMID: 10.1016/j.atherosclerosis.2017.03.042)
Sakuma M, Endo N, Oinuma T, Hayami T, Endo E, Yazawa T, Watanabe K, Watanabe S (2006) Vitamin D and intact PTH status in patients with hip fracture. Osteoporos Int 17:1608–1614. (PMID: 10.1007/s00198-006-0167-1)
Jansz TT, Goto NA, van Ballegooijen AJ, Willems HC, Verhaar MC, van Jaarsveld BC (2019) The prevalence and incidence of vertebral fractures in end-stage renal disease and the role of parathyroid hormone. Osteoporos Int 32:635–643.
Fusaro M, Gallieni M, Aghi A, Rizzo MA, Iervasi G, Nickolas TL, Fabris F, Mereu MC, Giannini S, Sella S, Giusti A, Pitino A, D’Arrigo G, Rossini M, Gatti D, Ravera M, di Lullo L, Bellasi A, Brunori G, Piccoli A, Tripepi G, Plebani M (2019) Osteocalcin (bone GLA protein) levels, vascular calcifications, vertebral fractures and mortality in hemodialysis patients with diabetes mellitus. J Nephrol 32:635–643. (PMID: 10.1007/s40620-019-00595-1)
Fusaro M, Crepaldi G, Maggi S, Galli F, D'Angelo A, Calo L, Giannini S, Miozzo D, Gallieni M (2011) Vitamin K, bone fractures, and vascular calcifications in chronic kidney disease: an important but poorly studied relationship. J Endocrinol Investig 34:317–323. (PMID: 10.1007/BF03347093)
Lau EMC, Dinavahi R, Woo YC, Wu CH, Guan J, Maddox J, Tolman C, Yang W, Shin CS (2020) Romosozumab or alendronate for fracture prevention in east Asian patients: a subanalysis of the phase III, randomized ARCH study. Osteoporos Int 31:677–685. (PMID: 10.1007/s00198-020-05324-0)
Lv F, Cai X, Yang W, Gao L, Chen L, Wu J, Ji L (2020) Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta- analysis. Bone 130:115121. (PMID: 10.1016/j.bone.2019.115121)
Rodriguez-Garcia M, Gomez-Alonso C, Naves-Diaz M, Diaz-Lopez JB, Diaz-Corte C, Cannata-Andia JB, Asturias Study G (2009) Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrol Dial Transplant 24:239–246. (PMID: 10.1093/ndt/gfn466)
Torres A, Torregrosa V, Marcen R, Campistol JM, Arias M, Hernández D, Fernández C, Esforzado N, Paschoalin R, Pérez N, García AI, del Amo M, Pomés J, González Rinne A, Marrero D, Pérez E, Henríquez F, Díaz JM, Silva I, López V, Perello M, Ramos D, Beneyto I, Cruzado JM, Martínez Castelao A, Bravo J, Rodríguez M, Díaz C, Crespo J, Anaya F, Rodríguez ML, Cubero JJ, Pascual P, Romero R, Andrés Belmonte A, Checa MD, Jiménez C, Escuin F, Crespo M, Mir M, Gómez G, Bayes B, González MJ, Gutiérrez A, Cuberes M, Rodríguez Benoit A, García T, Llamas F, Ortega A, Conde JL, Gómez Alamillo C (2016) Mineral metabolism disorders, vertebral fractures and aortic calcifications in stable kidney transplant recipients: the role of gender (EMITRAL study). Nefrologia 36:255–267. (PMID: 10.1016/j.nefro.2016.03.004)
Magnus JH, Broussard DL (2005) Relationship between bone mineral density and myocardial infarction in US adults. Osteoporos Int 16:2053–2062. (PMID: 10.1007/s00198-005-1999-9)
Farhat GN, Newman AB, Sutton-Tyrrell K, Matthews KA, Boudreau R, Schwartz AV, Harris T, Tylavsky F, Visser M, Cauley JA, for the Health ABC study (2007) The association of bone mineral density measures with incident cardiovascular disease in older adults. Osteoporos Int 18:999–1008. (PMID: 10.1007/s00198-007-0338-8)
Hong WJ, Chen W, Yeo KJ, Huang PH, Chen DY, Lan JL (2019) Increased risk of osteoporotic vertebral fracture in rheumatoid arthritis patients with new-onset cardiovascular diseases: a retrospective nationwide cohort study in Taiwan. Osteoporos Int 30:1617–1625. (PMID: 10.1007/s00198-019-04966-z)
Makovey J, Macara M, Chen JS, Hayward CS, March L, Sambrook PN (2013) High osteoporotic fracture risk and CVD risk co-exist in postmenopausal women. Bone 52:120–125. (PMID: 10.1016/j.bone.2012.09.025)
Chen YC, Wu JC, Liu L, Huang WC, Cheng H, Chen TJ, Thien PF, Lo SS (2013) Hospitalized osteoporotic vertebral fracture increases the risk of stroke: a population-based cohort study. J Bone Miner Res 28:516–523. (PMID: 10.1002/jbmr.1722)
Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C (2000) Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58:396–399. (PMID: 10.1046/j.1523-1755.2000.00178.x)
Naylor KL, McArthur E, Leslie WD, Fraser LA, Jamal SA, Cadarette SM, Pouget JG, Lok CE, Hodsman AB, Adachi JD, Garg AX (2014) The three-year incidence of fracture in chronic kidney disease. Kidney Int 86:810–818. (PMID: 10.1038/ki.2013.547)
Fusaro M, Tripepi G, Noale M, Vajente N, Plebani M, Zaninotto M, Guglielmi G, Miotto D, Carbonare LD, D’Angelo A, Ciurlino D, Puggia R, Miozzo D, Giannini S, Gallieni M (2013) High prevalence of vertebral fractures assessed by quantitative morphometry in hemodialysis patients, strongly associated with vascular calcifications. Calcif Tissue Int 93:39–47. (PMID: 10.1007/s00223-013-9722-x)
Raggi P, Vukicevic S, Moyses RM, Wesseling K, Spiegel DM (2010) Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol 5(Suppl 1):S31–S40. (PMID: 10.2215/CJN.05880809)
Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Drüeke TB, Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators (2015) Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial. J Am Soc Nephrol 26:1466–1475. (PMID: 10.1681/ASN.2014040414)
Evans M, Methven S, Gasparini A, Barany P, Birnie K, MacNeill S, May MT, Caskey FJ, Carrero JJ (2018) Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism. Sci Rep 8:2103. (PMID: 10.1038/s41598-018-20552-5)
Miller P, Chines A, Albergaria B-H, Gielen E, Langdahl B, Miyauchi A, Vanderkelen M, Milmont CE, Maddox J, Adachi J (2019) Efficacy and safety of romosozumab vs placebo among patients with mild-to-moderate chronic kidney disease. J Bone Miner Res 32 (Suppl 1) Abvailable at https://www.asbmr.org/education/2019-abstracts . Access April 12, 2020.
Cosman F, Crittenden DB, Ferrari S, Lewiecki EM, Jaller-Raad J, Zerbini C, Milmont CE, Meisner PD, Libanati C, Grauer A (2018) Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J Bone Miner Res 33:1407–1416. (PMID: 10.1002/jbmr.3439)
Paloian NJ, Giachelli CM (2014) A current understanding of vascular calcification in CKD. Am J Physiol Renal Physiol 307:F891–F900. (PMID: 10.1152/ajprenal.00163.2014)
Reiss AB, Miyawaki N, Moon J, Kasselman LJ, Voloshyna I, D'Avino R Jr, De Leon J (2018) CKD, arterial calcification, atherosclerosis and bone health: inter-relationships and controversies. Atherosclerosis 278:49–59. (PMID: 10.1016/j.atherosclerosis.2018.08.046)
Szulc P, Samelson EJ, Sornay-Rendu E, Chapurlat R, Kiel DP (2013) Severity of aortic calcification is positively associated with vertebral fracture in older men--a densitometry study in the STRAMBO cohort. Osteoporos Int 24:1177–1184. (PMID: 10.1007/s00198-012-2101-z)
Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V (2004) Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 89:4246–4253. (PMID: 10.1210/jc.2003-030964)
El Maghraoui A, Rezqi A, Mounach A, Achemlal L, Bezza A, Dehhaoui M, Ghozlani I (2013) Vertebral fractures and abdominal aortic calcification in postmenopausal women. A cohort study Bone 56:213–219. (PMID: 23756234)

N/A The Korean Society of Nephrology

Keywords: Fracture; Hemodialysis; Myocardial infarction; Vertebral

Date Created: 20200513 Date Completed: 20210303 Latest Revision: 20211019

20240829

10.1007/s00198-020-05423-y

32394062